Masitinib found superior to standard GIST treatment: AB Science reports
AB Science's investigational drug, Masitinib has showed improved overall survival in patients with Gleevec-resistant gastrointestinal stromal tumors (GIST).
Masitinib is an investigational orally administered tyrosine kinase inhibitor that targets mast cells, essential for immunity.
In the study, 44 patients with inoperable, locally advanced or metastatic GIST received either Masitinib at 12 mg/kg/day or Pfizer's Sutent drug, currently the standard of care for GIST patients.
The study showed that after a median follow-up of 14 months, median overall survival was not reached for Masitinib versus 15 months for Sutent, while after two years, 53% of patients treated with Masitinib were still alive, compared to 0% for the patients treated with Sutent.
The trial also demonstrated that Masitinib reported good safety profile with a significantly longer Safety Event Free Survival and a lower occurrence of severe adverse events compared to Sutent.
AB Science Scientific Committee president Olivier Hermine said Masitinib differs from Sutent by its selectivity profile, with a complementary mode of action to kill cancer stem cells and trigger an immune response.
Related Insight
Suppliers Directory
Multipharma - Global Clinical Trial Supply and Comparator Drug Sourcing
Specialising in comparator drug sourcing activities while supporting the industry's global clinical supply chain.
Contract Research & Services > Clinical Trials > Suppliers
Toxikon Europe - Preclinical Safety Studies and QC Testing for the Life Science Community
For more than 30 years Toxikon has been a leading contract research organisation (CRO) providing high-quality preclinical safety studies to the life science community.
Contract Research & Services > Clinical Trials > Suppliers
MEDIDATA GmbH – CRO for Phase II to Phase IV Clinical Trials
MEDIDATA GmbH is a contract research organisation (CRO) that has been providing end-to-end services for phase II to phase IV clinical trials and for observational studies for more than 25 years.
Contract Research & Services > Clinical Trials > Suppliers
Asterand - Human Tissue and Human Tissue-Based Research Services
Asterand plc is the leading global supplier of high quality, well characterised human tissue and human tissue-based research services to drug discovery scientists.
Contract Research & Services > Clinical Trials > Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Clinical Trials Intelligence
TOX-RAY Screener Database
Published by Toxikon Europe PBR
Contract Research & Services > Clinical Trials > White Papers
Taming China's Clinical Trial 'Dragon'
Published by World Courier
Contract Research & Services > Clinical Trials > White Papers
Efficacy and Surgical Research Services (ESRS)
Published by Toxikon Europe
Contract Research & Services > Clinical Trials > White Papers
A New Approach to Outsourced Drug Development
Published by INC Research
Contract Research & Services > Clinical Trials > White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.